Headache News

Metoclopramide plus diphenhydramine resulted in greater improvement in pain scores compared with placebo for patients with acute post-traumatic headache in the ED, according to findings from a parallel group study published in Neurology.

Children and young adults who experience post-traumatic headache with migraine phenotype may be at increased risk for more significant injury or deleterious pathophysiology after concussion.

Neurological symptoms were among the most common clinical manifestations of COVID-19, with anosmia, myalgia and headache being the most frequently reported, data show.

Patients with migraine who were given opioids in the ED were more likely to return to the ED in the next 6 months compared with patients who were not prescribed opioids, according to findings from single-center, retrospective cohort study.

Cannabis use ”significantly contributes” to the prevalence of medication overuse headache among patients with chronic migraine, according to study results scheduled for presentation at the American Academy of Neurology Annual Meeting.

In a recent social media survey, 90% of patients with migraine said they use complementary and integrative medicines like meditation, yoga and vitamins, but only about 20% discuss these treatment strategies with a health care provider.

The FDA granted 510(k) clearance to electroCore to expand the approval of gammaCore, the company’s non-invasive vagus nerve stimulation, for the acute and preventative treatment of adolescent migraine, according to a press release.

The FDA has expanded the approval of a remote electrical neuromodulation device to treat episodic and chronic migraine in children aged 12 years and older, according to a press release issued by the manufacturer.

The FDA accepted a new drug application for INP104 for the acute treatment of migraine with or without aura in adults, Impel NeuroPharma announced.

Many neurostimulation methods have been developed for the prevention and treatment of migraine and while some appear to be useful, the quality of available evidence for most is poor, according to a study published in The Journal of Headache and Pain.